Running a 2,000 patient study, with average risk patients in the U.S., to read out by the end of 2025 (eAArly DETECT 2). With eAArly DETECT 2, the Company addresses FDA feedback and prepares for a new ...

Reports FY24 revenue $893,991 vs $895,479 last year. “We are proud of the accomplishments our team achieved in 2024, which was a transitional ...

Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe Operating loss ...

Average-Risk Patient Study Seeks to Confirm Mainz Biomed's Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples Study is on Track to Report ...

Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous ...

Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.58 per share a year ...

RIT’s biomedical sciences BS consists of life sciences core courses combined with flexible electives to customize your degree for medical school or full-time employment. Prepare for Advanced Degrees: ...

Immunome, Inc. (IMNM) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.54 per share a year ago. These figures are ...

Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA ApprovalBERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed ...

BERKELEY, Calif. - Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company with a market capitalization of $16.47 million, has entered into an exclusive licensing agreement with ...

(RTTNews) - Mainz Biomed N.V. (MYNZ), a molecular genetics diagnostic company specializing in early cancer detection, announced Thursday that it has entered into an exclusive licensing agreement ...